Jiangxi Institute of Biological Products Inc. (HKG:6915)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Pharmaceuticals	235.41M	220.76M	198.02M
Pharmaceuticals Growth	6.64%	11.48%	-
Total	235.41M	220.76M	198.02M
Total Growth	6.64%	11.48%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Chinese Mainland	222.98M	212.73M	195.00M
Chinese Mainland Growth	4.81%	9.09%	-
Overseas	12.43M	8.02M	3.02M
Overseas Growth	54.97%	165.75%	-
Total	235.41M	220.76M	198.02M
Total Growth	6.64%	11.48%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jul 16, 2026

Data Sources Report a data error